Copper Cu 64-Dota-Pembrolizumab
Metastatic Malignant Neoplasm
Explore 273 assets in Metastatic Malignant Neoplasm →Floatz Rating
C36/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
radiopharmaceutical
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05728372CT.gov 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Copper Cu 64-Dota-Pembrolizumab (this asset) | City of Hope Medical Center | Early P1 | C · 36 |
| Fluorouracilum | I-Mab Biopharma US Limited | P3 | BB |
| Nivestim | Mayo Clinic | P3 | BB |
| Irinotecan | Incyte Corporation | P3 | BB |
| Dexasone | Genmab | P3 | BB |
| Pembrolizumab | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Cyclophosphamide | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Ipilimumab | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Oxaliplatin | I-Mab Biopharma US Limited | P3 | BB |
+42 more in the Metastatic Malignant Neoplasm cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Copper Cu 64-Dota-Pembrolizumab in Metastatic Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/copper-cu-64-dota-pembrolizumab-metastatic-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →